Literature DB >> 11728691

Cervical lymph node relapses of head-and-neck squamous cell carcinoma: is brachytherapy a therapeutic option?

M A Bollet1, M Lapeyre, C Marchal, S Hoffstetter, D Peiffert, P G Cornes, E Luporsi, P Bey.   

Abstract

PURPOSE: To report the results of interstitial brachytherapy (IBT) without salvage surgery for isolated cervical lymph node relapses. PATIENT AND METHODS: From 1970 to 1989, 84 patients were treated; 76 patients had relapsed in sites of previous external beam radiation. In 72 patients, IBT was sole salvage treatment (mean, 56.5 Gy). In 12 patients IBT (mean, 38 Gy) was combined with further external beam radiotherapy (mean, 41 Gy).
RESULTS: Local control in the neck was 49% at 1 year, 31% at 2 years, and 0% at 5 years. Overall survival was 33% at 1 year, 13% at 2 years, and 1% at 5 years. Significant toxicity occurred in 35% (7% fatal). Multivariate analysis shows survival after salvage was better for patients who had achieved initial control for > or =18 months before relapse (0% vs. 13% at 3 years, p < 0.0002). Lymph node control was better for patients who received total salvage dose > or =60 Gy (0% vs. 56% at 3 years, p = 0.0004).
CONCLUSION: Given its poor efficiency and its toxicity, IBT must be considered only when surgery is contraindicated and if lymph node relapse occurs after a minimal interval of 18 months.

Entities:  

Mesh:

Year:  2001        PMID: 11728691     DOI: 10.1016/s0360-3016(01)01725-4

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  Intensity modulated perioperative HDR brachytherapy for recurrent and/or advanced head and neck metastases.

Authors:  Ingo U Teudt; György Kovàcs; Matthias Ritter; Corinna Melchert; Tamer Soror; Barbara Wollenberg; Jens E Meyer
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-10-23       Impact factor: 2.503

2.  Reirradiation for recurrent head and neck cancer with salvage interstitial pulsed-dose-rate brachytherapy: Long-term results.

Authors:  Vratislav Strnad; Michael Lotter; Stephan Kreppner; Rainer Fietkau
Journal:  Strahlenther Onkol       Date:  2015-01-10       Impact factor: 3.621

3.  Neither high-dose nor low-dose brachytherapy increases flap morbidity in salvage treatment of recurrent head and neck cancer.

Authors:  Peter W Henderson; David I Kutler; Bhupesh Parashar; David M Otterburn; Marc A Cohen; Jason A Spector
Journal:  J Contemp Brachytherapy       Date:  2016-08-29

4.  The role of salvage surgery with interstitial brachytherapy for the Management of Regionally Recurrent Head and Neck Cancers.

Authors:  Nayel Khan; Mark Clemens; Jun Liu; Adam S Garden; Anne Lawyer; Randal Weber; G Brandon Gunn; William H Morrison; Michael E Kupferman
Journal:  Cancers Head Neck       Date:  2019-07-22

Review 5.  A systematic review of treating recurrent head and neck cancer: a reintroduction of brachytherapy with or without surgery.

Authors:  Julianna Rodin; Voichita Bar-Ad; David Cognetti; Joseph Curry; Jennifer Johnson; Chad Zender; Laura Doyle; David Kutler; Benjamin Leiby; William Keane; Adam Luginbuhl
Journal:  J Contemp Brachytherapy       Date:  2018-10-31

6.  Single institution implementation of permanent 131Cs interstitial brachytherapy for previously irradiated patients with resectable recurrent head and neck carcinoma.

Authors:  Voichita Bar-Ad; Emily Hubley; Adam Luginbuhl; David Cognetti; Joseph Curry; Amy S Harrison; Jennifer M Johnson; James Keller; Cheng Peng; David To; Laura Doyle
Journal:  J Contemp Brachytherapy       Date:  2019-06-28

7.  Carotid dosimetry after re-irradiation with 131Cs permanent implant brachytherapy in recurrent, resected head and neck cancer.

Authors:  Amanda Walsh; Emily Hubley; Laura Doyle; David Cognetti; Joseph Curry; Voichita Bar-Ad; Adam Luginbuhl
Journal:  J Contemp Brachytherapy       Date:  2019-06-28

8.  Reirradiation of recurrent head and neck cancer using high-dose-rate brachytherapy.

Authors:  V Rudzianskas; A Inciura; E Juozaityte; M Rudzianskiene; R Kubilius; S Vaitkus; M Kaseta; D Adliene
Journal:  Acta Otorhinolaryngol Ital       Date:  2012-10       Impact factor: 2.124

9.  Cesium-131 brachytherapy in high risk and recurrent head and neck cancers: first report of long-term outcomes.

Authors:  Anthony Pham; Shruthi Arora; A Gabriella Wernicke; David I Kutler; Marc Cohen; William Kuhel; Samuel Trichter; Dattatreyudu Nori; Silvia C Formenti; Bhupesh Parashar
Journal:  J Contemp Brachytherapy       Date:  2015-12-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.